VedTechBio Unveils Enhanced RxAgentAI for Faster Drug Discovery
VedTechBio Research Pvt. Ltd. has announced enhancements to its RxAgentAI platform, drastically reducing drug discovery timelines. The company has partnered with AlphaMeld Corporation to co-develop therapies, leveraging AI's power for metabolic and rare diseases. This advancement poises VedTechBio for significant market impact through strategic collaboration.
BENGALURU, India — VedTechBio Research Pvt. Ltd. has unveiled significant enhancements to its groundbreaking RxAgentAI platform, promising to cut drug discovery timelines in half. This AI-driven innovation synchronizes human expertise with intelligent agent outputs, aiming for unparalleled efficiency and accuracy in drug development processes.
As part of a strategic collaboration, VedTechBio has joined forces with AlphaMeld Corporation to co-develop multiple therapies targeting metabolic and rare diseases. This alliance capitalizes on the combined strengths of both companies, pairing AI-enabled discovery with real-world execution from preclinical stages to human proof-of-concept.
The enhanced RxAgentAI system positions VedTechBio to capture significant market value as it actively engages with major pharmaceutical companies in the US and EU. With its ability to deliver drug candidates efficiently and cost-effectively, VedTechBio stands to enhance its competitive edge in the burgeoning AI drug discovery market.
(With inputs from agencies.)
Google News